title: Tricuspid valve replacement with the St. Jude Medical valve: 19 years of experience.
abstract: OBJECTIVE
  The choice of the valve substitute in the tricuspid position remains controversial. A St. Jude Medical valve is a choice of valve substitute and its lower thrombogenicity and excellent hemodynamic performance have been reported even in the tricuspid position. However, little is known of the long-term durability of the St. Jude Medical valve in the tricuspid position. Our long-term experience of tricuspid valve replacement showed the higher thrombogenicity than we had expected, therefore, this study was done to reconsider our strategy for valve choice.
  
  
  METHODS
  This study reviewed 23 patient who underwent 25 tricuspid valve replacements with the St. Jude Medical valves from 1980 to 1997. The mean age was 40 years. Eleven patients (48%) were men. There were four in-hospital deaths (17%). The remaining 19 patients were all alive and followed from 2.2 to 19.0 years (mean 11.8 years).
  
  
  RESULTS
  The overall survival, including hospital mortality, was 83%, 10 and 15 years after surgery. Valve thrombosis occurred in six patients. Freedom from valve thrombosis was 78 and 70%, 10 and 15 years after surgery, respectively. The linearized rate of the valve thrombosis was 2.9%/patient-years. Six patients required reoperation. The mean interval to reoperation was 9.5 years. Freedom from reoperation was 83% and 75%, 10 and 15 years after surgery, respectively. The linearized rate of the reoperation was 2.8%/patient-years. No structural valve deterioration was found. Echocardiographic study showed that the function of the St. Jude Medical valve without valve-related complications was well maintained.
  
  
  CONCLUSIONS
  The higher thrombogenicity of the St. Jude Medical valve in the tricuspid position altered our choice of valve substitutes from the St. Jude Medical valve to a bioprosthesis which is lack of need for anticoagulant therapy except for juvenile patients who are able to maintain potent anticoagulant therapy.
authors.affiliation: Department of Surgery, Kurume University School of Medicine, Kurume, Japan. hkawano@qmed.hosp.go.jp
authors.forename: H
authors.initials: H
authors.lastname: Kawano
authors.forename: T
authors.initials: T
authors.lastname: Oda
authors.forename: S
authors.initials: S
authors.lastname: Fukunaga
authors.forename: E
authors.initials: E
authors.lastname: Tayama
authors.forename: T
authors.initials: T
authors.lastname: Kawara
authors.forename: A
authors.initials: A
authors.lastname: Oryoji
authors.forename: S
authors.initials: S
authors.lastname: Aoyagi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000209:etiology; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects* / Q000295:instrumentation* / Q000401:mortality; D006439:Hemodynamics; D017052:Hospital Mortality; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D012086:Reoperation; D016019:Survival Analysis; D013927:Thrombosis / Q000209:etiology; D016896:Treatment Outcome; D014262:Tricuspid Valve Insufficiency / Q000145:classification / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D014264:Tricuspid Valve Stenosis / Q000145:classification / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*